Dr. Evan Unger is Co-Founder, and Executive Chairman of NuvOx Therapeutics, a clinical stage biotechnology company developing oxygen therapeutics. He is also Founder and CEO of Microvascular Therapeutics, Inc. a clinical stage company developing contrast agents and theranostic products. Dr. Unger has founded four biotechnology companies. His first company, ImaRx Pharmaceutical, developed 3 FDA approved drugs and was acquired by DuPont yielding > 20x ROI. ImaRx Pharmaceutical developed Perflutren the world’s #1 selling ultrasound contrast agent, marketed by Lantheus. When Dr. Unger sold ImaRx Pharmaceutical to DuPont, he retained the therapeutic rights to Perflutren (perfluoropropane microbubbles) and launched his second company, ImaRx Therapeutics, which went public and performed clinical trials using innovative new technology - microbubbles with ultrasound (sonothrombolysis) to treat ischemic stroke. Based upon his pioneering work on microbubbles, Dr. Unger discovered that microbubbles carry far more oxygen than liquids. Therefore, Dr. Unger co-founded NuvOx to develop NanO2™, the world’s most effective oxygen therapeutic (fluorocarbon nanobubbles for oxygen delivery). NanO2 completed Phase IIa clinical trials in brain cancer as a radiosensitizer and in stroke as a neuroprotectant, showing safety and efficacy in both indications. NuvOx is currently conducting Phase IIb clinical trial in brain cancer (supported in part by the NCI), Phase IIb trial in stroke supported by the NIHR in the UK and a Phase Ib trial in respiratory distress in Canada supported by BARDA. Dr. Unger founded Microvascular Therapeutics (MVT) to develop a new, improved ultrasound contrast agent, CardiSon (which has finished Phase II trial, supported in part by the NHLBI), and theranostic products. MVT is developing theranostic products for treatment of vascular disease and detection and treatment of diseases including cancer, Alzheimer’s and inflammatory diseases.